=>
Uploading C:\Program Files\Stnexp\Queries\10551564-amended.str




chain nodes :
11 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 18 19 20 21 22 23 24 25 26 27 28 29
chain bonds :
7-11 8-18 9-27 11-13 13-14 13-15 15-16 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 18-19 18-23 19-20 20-21 21-22
22-23 24-25 24-29 25-26 26-27 27-28 28-29
exact/norm bonds :
5-6 5-7 6-9 7-8 7-11 8-9 8-18 9-27 11-13 13-14 13-15 15-16 16-17
exact bonds :
24-25 24-29 25-26 26-27 27-28 28-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 18 : 24 :

Connectivity :
11:2 E exact RC ring/chain 16:2 E exact RC ring/chain
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom

L1 STRUCTURE UPLOADED

=> d his

FILE 'REGISTRY' ENTERED AT 15:28:10 ON 18 AUG 2008
L1 STRUCTURE UPLOADED
L3 48 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:29:20 ON 18 AUG 2008
L4 8 S L3

FILE 'REGISTRY' ENTERED AT 15:29:32 ON 18 AUG 2008

=> d l1




=> fil caplus

=> d l4 tot bib abs hitstr

√L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:923552 CAPLUS Full-text

DN 147:448607

TI Development of carboxylic acid replacements in indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase

AU Stansfield, Ian; Pompei, Marco; Conte, Immacolata; Ercolani, Caterina; Migliaccio, Giovanni; Jairaj, Mark; Giuliano, Claudio; Rowley, Michael; Narjes, Frank

CS IRBM (Merck Research Laboratories Rome), Rome, 00040, Italy

SO Bioorganic & Medicinal Chemistry Letters √(2007), 17(18), 5143-5149
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 147:448607

GI



I

AB Allosteric inhibition of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase enzyme has recently emerged as a viable strategy toward blocking replication of viral RNA in cell-based systems. We report here 2 series of indole-N-acetamides, bearing physicochem. diverse carboxylic acid replacements, which show potent affinity for the NS5B enzyme with reduced potential for formation of glucuronide conjugates. E.g., indole-N-acetamide I was prepared in several steps from Me 2-bromo-3-cyclohexyl-5-indolecarboxylate. Preliminary optimization of these series furnished compds. that are potent in the blockade of subgenomic HCV RNA replication in HUH-7 cells.

IT 774213-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of indole-N-acetamides as inhibitors of hepatitis C virus NS5B polymerase)

RN 774213-31-9 CAPLUS

CN 1H-Indole-1-acetamide, 3-cyclohexyl-6-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-methyl-N-[(1-methyl-3-piperidinyl)methyl]-2-phenyl- (CA INDEX NAME)



√L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:324208 CAPLUS Full-text

DN 147:497550

TI Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach

AU Gao, Y.-D.; Olson, S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.; Tang, W.; Hartley, D. P.; Mosley, R. T.

CS CIBE, Department of Molecular Systems, Merck Research Laboratories, Madrid, Spain

SO Xenobiotica √ (2007), 37(2), 124-138
CODEN: XENOBH; ISSN: 0049-8254
PB Informa Healthcare
DT Journal
LA English
AB Recent studies have demonstrated that the pregnane X receptor (PXR) is a key regulator of cytochromes P 450 3A (e.g. CYP3A4 in human) gene expression. As a result, activation of PXR may lead to CYP3A4 protein over-expression. Because induction of CYP3A4 could result in clin. important drug-drug interactions, there has been a great interest in reducing the possibility of PXR activation by drug candidates in drug-discovery programs. In order to provide structural insight for attenuating drug candidate-mediated PXR activation, we used a docking approach to study the structure-activity relationship for PXR activators. Based on our docking models, it is proposed that introducing polar groups to the end of an activator should reduce its human PXR (hPXR) activity via destabilizing interactions in the hydrophobic areas of the PXR ligand-binding pocket. A number of analogs that incorporate these structural features then were designed and synthesized, and they exhibited significantly lower hPXR activation in a transactivation assay and decreased CYP3A4 induction in a human hepatocytes-based assay. In addition, an example in which attenuating hPXR activation was achieved by sterically destabilizing the helixes 11 and 12 of the receptor is presented.
IT 774210-59-2 861966-03-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(mol. modeling of pregnane X receptor (PXR) regulation)
RN 774210-59-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)




RN 861966-03-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2-(4-chlorophenyl)-3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]- (CA INDEX NAME)



√L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:834581 CAPLUS Full-text

DN 145:410005

TI Parallel Screening: A Novel Concept in Pharmacophore Modeling and Virtual Screening

AU Steindl, Theodora M.; Schuster, Daniela; Laggner, Christian; Langer, Thierry

CS Institute of Phamacy, Computer Aided Molecular Design Group, University of Innsbruck, Innrain, Austria

SO Journal of Chemical Information and Modeling √ (2006), 46(5), 2146-2157
CODEN: JCISD8; ISSN: 1549-9596

PB American Chemical Society

DT Journal

LA English

AB Parallel screening comprises a novel in silico method to predict the potential biol. activities of a compound by screening it with a multitude of pharmacophore models. Our aim is to provide a fast, large-scale system that allows for virtual activity profiling. In this proof of principle study, carried out with the software tools LigandScout and Catalyst, the authors present a model work for the application of parallel pharmacophore-based virtual screening on a set of 50 structure-based pharmacophore models built for various viral targets and 100 antiviral compds. The latter were screened against all pharmacophore models in order to determine if their biol. targets could be correctly predicted via an enrichment of corresponding pharmacophores matching these ligands. The results demonstrate that the desired enrichment, i.e., successful virtual activity profiling, was achieved for approx. 90% of all input mols. The authors discuss descriptors for output validation, as well as various aspects influencing the anal. of the obtained activity profiles, and the effect of the utilized search modus for screening.

IT 912462-96-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(parallel screening, a concept in pharmacophore modeling and virtual screening)

RN 912462-96-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[[(3R)-1-methyl-3-piperidinyl]methyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




√L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:272517 CAPLUS Full-text

DN 144:311906

TI Preparation of indoleacetamides as antivirals for treatment of hepatitis C infection.

IN Colarusso, Stefania; Conte, Immacolata; Habermann, Joerg; Narjes, Frank; Ponzi, Simona

PA Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Italy

SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2006029912 | A1 | 20060323 | WO 2005-EP52631 | 20050608 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | AU 2005284248 | A1 | 20060323 | AU 2005-284248 | 20050608 |
| | CA 2568832 | A1 | 20060323 | CA 2005-2568832 | 20050608 |
| | EP 1758857 | A1 | 20070307 | EP 2005-811114 | 20050608 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV | | | | |
| | CN 1964944 | A | 20070516 | CN 2005-80019084 | 20050608 |
| | JP 2008501767 | T | 20080124 | JP 2007-526425 | 20050608 |
| | IN 2006DN07856 | A | 20070817 | IN 2006-DN7856 | 20061226 |
| PRAI | GB 2004-13087 | A | 20040611 | | |
| | WO 2005-EP52631 | W | √20050608 | | |

OS MARPAT 144:311906

GI



I

AB Title compds. [I; E = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) (hetero)aryl; A = (substituted) alkyl, alkenyl, nonarom. ring; R1, R2 = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkylalkyl, etc.; R3 = H, alkyl, alkenyl; R4 = H, alkyl; X = DBCR5R6; R5, R6 = H, halo, alkyl, alkenyl, alkoxy; B = (substituted) aryl, heteroaryl, etc.; D = bond, alkylene, alkenylene, alkynylene, (substituted) aryl, heteroaryl], were prepared Thus, title compound (2E)-3-[4-[[[1-[[[3-cyclohexyl-1-[2- (dimethylamino)-2-oxoethyl]-2-phenyl-1H-indol-6- yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]acrylic acid was prepared in 8 steps from Me indole-6-carboxylate, cyclohexanone, phenylboronic acid, 2-chloro-N,N-dimethylacetamide, 1-[[(benzyloxy)carbonyl]amino]cyclopentanecarboxylic acid, and Et cinnamate. I generally showed IC50's of <1 μM for inhibition of HCV RNA dependent RNA polymerase (NS5B).

IT 879498-47-2P 879498-61-0P 879498-65-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of indoleacetamides as antivirals for treatment
of hepatitis C infection)

RN 879498-47-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-1H-indol-6-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 879498-61-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[3-cyclohexyl-1-[2-oxo-2-[[(5-oxo-2-pyrrolidinyl)methyl]amino]ethyl]-2-phenyl-1H-indol-6-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (CA INDEX

NAME)

Double bond geometry as shown.



RN 879498-65-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[3-cyclohexyl-1-[2-[(1,4-dioxan-2-ylmethyl)amino]-2-oxoethyl]-2-phenyl-1H-indol-6-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



√L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:760643 CAPLUS Full-text
DN 143:341687
TI Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site
AU Di Marco, Stefania; Volpari, Cinzia; Tomei, Licia; Altamura, Sergio; Harper, Steven; Narjes, Frank; Koch, Uwe; Rowley, Michael; De Francesco,

Raffaele; Migliaccio, Giovanni; Carfi, Andrea
CS Istituto di Ricerche di Biologia Molecolare P. Angeletti, Pomezia (Rome), 00040, Italy
SO Journal of Biological Chemistry √ (2005), 280(33), 29765-29770
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB The hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase is required for replication of the viral genome and is a key target for therapeutic intervention against HCV. We have determined the crystal structures of the HCV polymerase complexed with two indole-based allosteric inhibitors at 2.3- and 2.4-Å resolution The structures show that these inhibitors bind to a site on the surface of the thumb domain. A cyclohexyl and Ph ring substituents, bridged by an indole moiety, fill two closely spaced pockets, whereas a carboxylate substituent forms a salt bridge with an exposed arginine side chain. Interestingly, in the apoenzyme, the inhibitor binding site is occupied by a small α-helix at the tip of the N-terminal loop that connects the fingers and thumb domains. Thus, these mols. inhibit the enzyme by preventing formation of intramol. contacts between these two domains and consequently precluding their coordinated movements during RNA synthesis. Our structures identify a novel mechanism by which a new class of allosteric inhibitors inhibits the HCV polymerase and open the way to the development of novel antiviral agents against this clin. relevant human pathogen.
IT 774210-59-2D, complexes with NS5B
RL: PRP (Properties)
(crystal structures reveal interdomain communication in HCV NS5B polymerase is disrupted by indole-based inhibitors bound to novel allosteric site)
RN 774210-59-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)




√L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:500671 CAPLUS Full-text
DN 143:211802
TI Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase
AU Harper, Steven; Avolio, Salvatore; Pacini, Barbara; Di Filippo, Marcello; Altamura, Sergio; Tomei, Licia; Paonessa, Giacomo; Di Marco, Stefania; Carfi, Andrea; Giuliano, Claudio; Padron, Julio; Bonelli, Fabio; Migliaccio, Giovanni; De Francesco, Raffaele; Laufer, Ralph; Rowley, Michael; Narjes, Frank
CS IRBM Merck Research Laboratories, Rome, 00040, Italy

SO Journal of Medicinal Chemistry √ (2005), 48(14), 4547-4557
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:211802
GI



I

AB Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. Compds. that block replication of subgenomic HCV RNA in liver cells are of interest because of their demonstrated antiviral effect in the clinic. In followup to a recent report that indole-N-acetamides were potent allosteric inhibitors of the HCV NS5B polymerase enzyme, the optimization as cell-based inhibitors are described. The crystal structure of I bound to NS5B was a guide in the design of a two-dimensional compound array that highlighted that formally zwitterionic inhibitors have strong intracellular potency and that pregnane X receptor (PXR) activation (an undesired off-target activity) was linked to a structural feature of the inhibitor. Optimized analogs devoid of PXR activation (EC50 = 127 nM) retain strong cell-based efficacy under high serum conditions and showed acceptable pharmacokinetics parameters in rat and dog.

IT 774210-60-5P 861966-04-3P 861966-27-0P
861966-47-4P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(preparation, subgenomic hepatitis C virus and viral NS5B polymerase inhibitory activity, and structure-activity relationship of indole-N-acetamide derivs. using either combinatorial chemical or solution-phase chemical)

RN 774210-60-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-59-2
CMF C31 H39 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 861966-04-3 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2-(4-chlorophenyl)-3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 861966-03-2
CMF C31 H38 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 861966-27-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774212-42-9
CMF C31 H39 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 861966-47-4 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-2-(3-fluorophenyl)-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774211-97-1
CMF C31 H38 F N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



√L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:141029 CAPLUS Full-text
DN 142:240430
TI Preparation of heterocyclic compounds as hepatitis C virus polymerase inhibitors
IN Oka, Takahiro; Yata, Shinji; Ikegashira, Kazutaka; Noji, Satoru; Akaki, Tatsuo; Hirashima, Shintaro; Niwa, Yasushi; Ando, Izuru; Sato, Toshihiro
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 467 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | √DATE |
|---|---|---|---|---|
| PI WO 2005014543 | A1 | 20050217 | WO 2004-JP11640 | 20040806 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2003-288296 A 20030806
JP 2003-288298 A 20030806

√L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:857606 CAPLUS Full-text
DN 141:350034
TI Preparation of indole acetamides as inhibitors of the hepatitis c virus NS5B polymerase
IN Avolio, Salvatore; Di Filippo, Marcello; Harper, Steven; Narjes, Frank; Pacini, Barbara; Pompei, Marco; Rowley, Michael; Stansfield, Ian
PA Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa, Italy
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004087714 | A1 | 20041014 | WO 2004-GB1437 | 20040402 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004226144 | A1 | 20041014 | AU 2004-226144 | 20040402 |
| | CA 2520896 | A1 | 20041014 | CA 2004-2520896 | 20040402 |
| | EP 1613634 | A1 | 20060111 | EP 2004-725422 | 20040402 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | JP 2007516158 | T | 20070621 | JP 2006-506078 | 20040402 |
| | IN 2005DN04494 | A | 20070824 | IN 2005-DN4494 | 20051004 |
| | US 20070167447 | A1 | 20070719 | √US 2006-551564 | 20060605 |

PRAI GB 2003-7891 A 20030404
WO 2004-GB1437 W 20040402
OS MARPAT 141:350034
GI



I



II

AB Title compds. represented by the formula I [wherein Ar1 = (un)substituted heteroaryl; A1 = (un)substituted alkyl, alkenyl, non-aromatic (bi)cyclic ring; R1, R2 = independently H, alkyl, alkenyl, alkynyl, etc.; n = 1-4; X1-X4 = N or (un)substituted carbon; and pharmaceutically acceptable salts thereof] were prepared as inhibitors of the hepatitis c virus (HCV) NS5B polymerase. For example, II was given in a multi-step synthesis starting from the reaction of Me 1H-indole-6-carboxylate with 3-bromocyclohex-1- ene. I were tested for inhibitory activity against the HCV RNA dependent RNA polymerase (NS5B) in an enzyme inhibition assay with IC50 below 5μM in the enzyme assay and EC50 below 20 pM in the cell based assay. Thus, I and their pharmaceutical compns. are useful as inhibitors of the hepatitis c virus NS5B polymerase for the prevention and treatment of hepatitis C infections.

IT 774210-51-4P 774210-57-0P 774210-60-5P
774210-63-8P 774210-66-1P 774210-69-4P
774210-75-2P 774211-22-2P 774211-44-8P
774211-50-6P 774211-97-1P 774212-18-9P
774212-22-5P 774212-42-9P 774213-31-9P
774213-35-3P 774213-72-8P 774214-26-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole acetamides as inhibitors of hepatitis c virus NS5B polymerase)

RN 774210-51-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[(1-methyl-3-pyrrolidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 774210-57-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[1-(3-methyl-1H-1,2,4-triazol-5-yl)ethyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-56-9
CMF C28 H31 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774210-60-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-59-2
CMF C31 H39 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774210-63-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-62-7
CMF C30 H37 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774210-66-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-2-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-65-0
CMF C31 H39 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774210-69-4 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(5-methyl-1H-imidazol-2-yl)methyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-68-3
CMF C29 H32 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774210-75-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[2-(1-methyl-3-pyrrolidinyl)ethyl]amino]-2-oxoethyl]-2-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 774210-74-1
CMF C30 H37 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 774211-22-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[1-(2-thiazolyl)ethyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)



RN 774211-44-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[2-(4-methyl-1-piperazinyl)ethyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)



RN 774211-50-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)



RN 774211-97-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-2-(3-fluorophenyl)-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]- (CA INDEX NAME)



RN 774212-18-9 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-2-[4-[2-(dimethylamino)-2-oxoethoxy]phenyl]-1-[2-[methyl(2-pyrazinylmethyl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 774212-22-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-2-(3-fluorophenyl)-1-[2-oxo-2-[[(tetrahydro-1,1-dioxido-3-thienyl)methyl]amino]ethyl]- (CA INDEX NAME)



RN 774212-42-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[(1-methyl-3-piperidinyl)methyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)



RN 774213-31-9 CAPLUS
CN 1H-Indole-1-acetamide, 3-cyclohexyl-6-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-methyl-N-[(1-methyl-3-piperidinyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 774213-35-3 CAPLUS
CN 1H-Indole-1-acetamide, 3-cyclohexyl-6-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-[(1-methyl-3-pyrrolidinyl)methyl]-2-phenyl- (CA INDEX NAME)



RN 774213-72-8 CAPLUS
CN 1H-Indole-1-acetamide, 3-cyclohexyl-N-methyl-N-[(1-methyl-3-piperidinyl)methyl]-2-phenyl-6-[[[(phenylmethyl)sulfonyl]amino]carbonyl]- (CA INDEX NAME)



RN 774214-26-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-cyclohexyl-1-[2-[methyl[1-(4-pyridinyl)ethyl]amino]-2-oxoethyl]-2-phenyl- (CA INDEX NAME)



```
=> log hold

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:30:00 ON 18 AUG 2008
```